Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.

Panoutsopoulou K, Avgeris M, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A.

Carcinogenesis. 2019 Oct 5. pii: bgz163. doi: 10.1093/carcin/bgz163. [Epub ahead of print]

PMID:
31586203
2.

Surface loops of trypsin-like serine proteases as determinants of function.

Goettig P, Brandstetter H, Magdolen V.

Biochimie. 2019 Nov;166:52-76. doi: 10.1016/j.biochi.2019.09.004. Epub 2019 Sep 7. Review.

PMID:
31505212
3.

Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors.

Bronger H, Magdolen V, Goettig P, Dreyer T.

Cancer Metastasis Rev. 2019 Sep;38(3):417-430. doi: 10.1007/s10555-019-09807-3. Review.

PMID:
31482487
4.

Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET.

Goldhardt O, Warnhoff I, Yakushev I, Begcevic I, Förstl H, Magdolen V, Soosaipillai A, Diamandis E, Alexopoulos P, Grimmer T.

Transl Neurodegener. 2019 Aug 27;8:25. doi: 10.1186/s40035-019-0168-6. eCollection 2019.

5.

Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.

Gong W, Liu Y, Seidl C, Diamandis EP, Kiechle M, Drecoll E, Kotzsch M, Magdolen V, Dorn J.

BMC Cancer. 2019 Jul 15;19(1):696. doi: 10.1186/s12885-019-5901-0.

6.

Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.

Gong W, Liu Y, Seidl C, Dreyer T, Drecoll E, Kotzsch M, Bronger H, Dorn J, Magdolen V.

PLoS One. 2019 Feb 27;14(2):e0212968. doi: 10.1371/journal.pone.0212968. eCollection 2019.

7.

Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome.

Silva LM, Kryza T, Stoll T, Hoogland C, Dong Y, Stephens CR, Hastie ML, Magdolen V, Kleifeld O, Gorman JJ, Clements JA.

Mol Cell Proteomics. 2019 May;18(5):818-836. doi: 10.1074/mcp.RA118.001304. Epub 2019 Jan 31.

PMID:
30705123
8.

Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer.

Schricker G, Napieralski R, Noske A, Piednoir E, Manner O, Schüren E, Lauber J, Perkins J, Magdolen V, Schmitt M, Ulm K, Weichert W, Kiechle M, Martens JWM, Wilhelm OG.

Sci Rep. 2018 Nov 15;8(1):16861. doi: 10.1038/s41598-018-34919-1.

9.
10.

Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.

Wang P, Magdolen V, Seidl C, Dorn J, Drecoll E, Kotzsch M, Yang F, Schmitt M, Schilling O, Rockstroh A, Clements JA, Loessner D.

Br J Cancer. 2018 Oct;119(7):1-9. doi: 10.1038/s41416-018-0260-1. Epub 2018 Oct 5.

11.

Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer.

Loessner D, Goettig P, Preis S, Felber J, Bronger H, Clements JA, Dorn J, Magdolen V.

Expert Opin Ther Targets. 2018 Sep;22(9):745-763. doi: 10.1080/14728222.2018.1512587. Epub 2018 Sep 6. Review.

PMID:
30114962
12.

Kallikrein-related peptidases are activators of the CC chemokine CCL14.

Grünberg M, Quandt D, Cynis H, Demuth HU, Kindermann A, Magdolen V, Forssmann WG, Seliger B, Mägert HJ.

Eur J Immunol. 2018 Sep;48(9):1592-1594. doi: 10.1002/eji.201747452. Epub 2018 Aug 22.

13.

Structural determinants of specificity and regulation of activity in the allosteric loop network of human KLK8/neuropsin.

Debela M, Magdolen V, Skala W, Elsässer B, Schneider EL, Craik CS, Biniossek ML, Schilling O, Bode W, Brandstetter H, Goettig P.

Sci Rep. 2018 Jul 16;8(1):10705. doi: 10.1038/s41598-018-29058-6.

14.

Activation and activity of glycosylated KLKs 3, 4 and 11.

Guo S, Briza P, Magdolen V, Brandstetter H, Goettig P.

Biol Chem. 2018 Sep 25;399(9):1009-1022. doi: 10.1515/hsz-2018-0148.

PMID:
29975661
15.

Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.

Begcevic I, Brinc D, Brown M, Martinez-Morillo E, Goldhardt O, Grimmer T, Magdolen V, Batruch I, Diamandis EP.

J Proteomics. 2018 Jun 30;182:12-20. doi: 10.1016/j.jprot.2018.04.027. Epub 2018 Apr 22.

PMID:
29684683
16.

Insights into the activity control of the kallikrein-related peptidase 6: small-molecule modulators and allosterism.

Soualmia F, Bosc E, Amiri SA, Stratmann D, Magdolen V, Darmoul D, Reboud-Ravaux M, El Amri C.

Biol Chem. 2018 Sep 25;399(9):1073-1078. doi: 10.1515/hsz-2017-0336.

PMID:
29641412
17.

Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.

Dettmar L, Ahmed N, Kotzsch M, Diersch S, Napieralski R, Darmoul D, Schmitt M, Weichert W, Kiechle M, Dorn J, Magdolen V.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1109-1118. doi: 10.1007/s00432-018-2623-7. Epub 2018 Mar 15.

PMID:
29546479
18.

Kallikrein-related peptidase 7 overexpression in melanoma cells modulates cell adhesion leading to a malignant phenotype.

Haddada M, Draoui H, Deschamps L, Walker F, Delaunay T, Brattsand M, Magdolen V, Darmoul D.

Biol Chem. 2018 Sep 25;399(9):1099-1105. doi: 10.1515/hsz-2017-0339.

PMID:
29498930
19.

PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.

Absmaier M, Napieralski R, Schuster T, Aubele M, Walch A, Magdolen V, Dorn J, Gross E, Harbeck N, Noske A, Kiechle M, Schmitt M.

Int J Oncol. 2018 Mar;52(3):755-767. doi: 10.3892/ijo.2018.4241. Epub 2018 Jan 8.

20.

Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases.

Reid JC, Matsika A, Davies CM, He Y, Broomfield A, Bennett NC, Magdolen V, Srinivasan B, Clements JA, Hooper JD.

Am J Cancer Res. 2017 Nov 1;7(11):2257-2274. eCollection 2017.

21.

The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.

Aubele M, Schmitt M, Napieralski R, Paepke S, Ettl J, Absmaier M, Magdolen V, Martens J, Foekens JA, Wilhelm OG, Kiechle M.

Dis Markers. 2017;2017:4934608. doi: 10.1155/2017/4934608. Epub 2017 Sep 12. Review.

22.

Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.

Geng X, Liu Y, Diersch S, Kotzsch M, Grill S, Weichert W, Kiechle M, Magdolen V, Dorn J.

PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017.

23.

Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.

Kotzsch M, Kirchner T, Soelch S, Schäfer S, Friedrich K, Baretton G, Magdolen V, Luther T.

Am J Cancer Res. 2017 Sep 1;7(9):1959-1970. eCollection 2017.

24.

Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer.

Yang F, Aubele M, Walch A, Gross E, Napieralski R, Zhao S, Ahmed N, Kiechle M, Reuning U, Dorn J, Sweep F, Magdolen V, Schmitt M.

Biol Chem. 2017 Sep 26;398(10):1151-1164. doi: 10.1515/hsz-2017-0122.

PMID:
28755528
25.

Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion.

Delaunay T, Deschamps L, Haddada M, Walker F, Soosaipillai A, Soualmia F, El Amri C, Diamandis EP, Brattsand M, Magdolen V, Darmoul D.

Mol Oncol. 2017 Oct;11(10):1330-1347. doi: 10.1002/1878-0261.12103. Epub 2017 Aug 11.

26.

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer.

De Marchi T, Timmermans MA, Sieuwerts AM, Smid M, Look MP, Grebenchtchikov N, Sweep FCGJ, Smits JG, Magdolen V, van Deurzen CHM, Foekens JA, Umar A, Martens JW.

Sci Rep. 2017 May 18;7(1):2099. doi: 10.1038/s41598-017-02296-w.

27.

Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.

Zhao S, Dorn J, Napieralski R, Walch A, Diersch S, Kotzsch M, Ahmed N, Hooper JD, Kiechle M, Schmitt M, Magdolen V.

Biol Chem. 2017 Jun 27;398(7):765-773. doi: 10.1515/hsz-2016-0282.

PMID:
27935848
28.

Structural basis for the Zn2+ inhibition of the zymogen-like kallikrein-related peptidase 10.

Debela M, Magdolen V, Bode W, Brandstetter H, Goettig P.

Biol Chem. 2016 Dec 1;397(12):1251-1264. doi: 10.1515/hsz-2016-0205.

29.

Preclinical evaluation of [111 In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.

Vangestel C, Thomae D, Van Soom J, Ides J, Wyffels L, Pauwels P, Stroobants S, Van der Veken P, Magdolen V, Joossens J, Augustyns K, Staelens S.

Contrast Media Mol Imaging. 2016 Nov;11(6):448-458. doi: 10.1002/cmmi.1706. Epub 2016 Aug 24.

PMID:
27558262
30.

In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B.

Reid JC, Bennett NC, Stephens CR, Carroll ML, Magdolen V, Clements JA, Hooper JD.

Biol Chem. 2016 Dec 1;397(12):1299-1305. doi: 10.1515/hsz-2016-0163.

PMID:
27533117
31.

Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.

Ahmed N, Dorn J, Napieralski R, Drecoll E, Kotzsch M, Goettig P, Zein E, Avril S, Kiechle M, Diamandis EP, Schmitt M, Magdolen V.

Biol Chem. 2016 Dec 1;397(12):1265-1276. doi: 10.1515/hsz-2016-0177.

32.

Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome.

Dorn J, Yassouridis A, Walch A, Diamandis EP, Schmitt M, Kiechle M, Wang P, Drecoll E, Schmalfeldt B, Loessner D, Kotzsch M, Magdolen V.

Am J Cancer Res. 2015 Dec 15;6(1):61-70. eCollection 2016.

33.

The solution structure of the kallikrein-related peptidases inhibitor SPINK6.

Jung S, Fischer J, Spudy B, Kerkow T, Sönnichsen FD, Xue L, Bonvin AM, Goettig P, Magdolen V, Meyer-Hoffert U, Grötzinger J.

Biochem Biophys Res Commun. 2016 Feb 26;471(1):103-8. doi: 10.1016/j.bbrc.2016.01.172. Epub 2016 Jan 30.

34.

A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity.

Guo S, Skala W, Magdolen V, Briza P, Biniossek ML, Schilling O, Kellermann J, Brandstetter H, Goettig P.

J Biol Chem. 2016 Jan 8;291(2):593-604. doi: 10.1074/jbc.M115.691097. Epub 2015 Nov 18.

35.

STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization.

Didiasova M, Zakrzewicz D, Magdolen V, Nagaraj C, Bálint Z, Rohde M, Preissner KT, Wygrecka M.

J Biol Chem. 2015 May 8;290(19):11983-99. doi: 10.1074/jbc.M114.598425. Epub 2015 Mar 24.

36.

Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.

Falkenberg N, Anastasov N, Schaub A, Radulovic V, Schmitt M, Magdolen V, Aubele M.

Oncotarget. 2015 Apr 10;6(10):8103-14.

37.

Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.

Fuessel S, Erdmann K, Taubert H, Lohse-Fischer A, Zastrow S, Meinhardt M, Bluemke K, Hofbauer L, Fornara P, Wullich B, Baretton G, Magdolen V, Wirth MP, Kotzsch M.

BMC Cancer. 2014 Dec 18;14:974. doi: 10.1186/1471-2407-14-974.

38.

Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity.

Skala W, Utzschneider DT, Magdolen V, Debela M, Guo S, Craik CS, Brandstetter H, Goettig P.

J Biol Chem. 2014 Dec 5;289(49):34267-83. doi: 10.1074/jbc.M114.598201. Epub 2014 Oct 16.

39.

Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer.

Walker F, Nicole P, Jallane A, Soosaipillai A, Mosbach V, Oikonomopoulou K, Diamandis EP, Magdolen V, Darmoul D.

Biol Chem. 2014 Sep;395(9):1075-86. doi: 10.1515/hsz-2014-0142.

PMID:
25153388
40.

Sweetened kallikrein-related peptidases (KLKs): glycan trees as potential regulators of activation and activity.

Guo S, Skala W, Magdolen V, Brandstetter H, Goettig P.

Biol Chem. 2014 Sep;395(9):959-76. doi: 10.1515/hsz-2014-0140. Review.

PMID:
25153382
41.

Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.

Al-Janabi O, Taubert H, Lohse-Fischer A, Fröhner M, Wach S, Stöhr R, Keck B, Burger M, Wieland W, Erdmann K, Wirth MP, Wullich B, Baretton G, Magdolen V, Kotzsch M, Füssel S.

Biomed Res Int. 2014;2014:972587. doi: 10.1155/2014/972587. Epub 2014 Apr 29.

42.

Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.

Dorn J, Beaufort N, Schmitt M, Diamandis EP, Goettig P, Magdolen V.

Crit Rev Clin Lab Sci. 2014 Apr;51(2):63-84. doi: 10.3109/10408363.2013.865701. Epub 2014 Feb 3. Review.

PMID:
24490956
43.

Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies.

Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, Scorilas A, Diamandis EP, Dorn J.

Radiol Oncol. 2013 Oct 8;47(4):319-29. doi: 10.2478/raon-2013-0053. eCollection 2013. Review.

44.

Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells.

Shahinian H, Loessner D, Biniossek ML, Kizhakkedathu JN, Clements JA, Magdolen V, Schilling O.

Mol Oncol. 2014 Feb;8(1):68-82. doi: 10.1016/j.molonc.2013.09.003. Epub 2013 Oct 1.

45.

Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer.

Dorn J, Gkazepis A, Kotzsch M, Kremer M, Propping C, Mayer K, Mengele K, Diamandis EP, Kiechle M, Magdolen V, Schmitt M.

Biol Chem. 2014 Jan;395(1):95-107. doi: 10.1515/hsz-2013-0172.

PMID:
23999494
46.

A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread.

Loessner D, Rizzi SC, Stok KS, Fuehrmann T, Hollier B, Magdolen V, Hutmacher DW, Clements JA.

Biomaterials. 2013 Oct;34(30):7389-400. doi: 10.1016/j.biomaterials.2013.06.009. Epub 2013 Jul 1.

PMID:
23827191
47.

Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies.

Dorn J, Bayani J, Yousef GM, Yang F, Magdolen V, Kiechle M, Diamandis EP, Schmitt M.

Thromb Haemost. 2013 Sep;110(3):408-22. doi: 10.1160/TH13-03-0206. Epub 2013 Jun 13. Review.

PMID:
23765253
48.

Impact of expression of the uPA system in sarcomas.

Taubert H, Magdolen V, Kotzsch M.

Biomark Med. 2013 Jun;7(3):473-80. doi: 10.2217/bmm.12.105. Review.

PMID:
23734810
49.

Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.

Grismayer B, Sato S, Kopitz C, Ries C, Soelch S, Schmitt M, Baretton G, Krüger A, Luther T, Kotzsch M, Magdolen V.

Biol Chem. 2012 Dec;393(12):1449-55.

PMID:
23667902
50.

Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.

Lehner A, Magdolen V, Schuster T, Kotzsch M, Kiechle M, Meindl A, Sweep FC, Span PN, Gross E.

PLoS One. 2013 Apr 8;8(4):e60359. doi: 10.1371/journal.pone.0060359. Print 2013.

Supplemental Content

Loading ...
Support Center